Classify one intended use before anyone compounds

When a veterinarian faces a difficult patient presentation—whether a canine patient with severe dysphagia requiring an oral liquid, a feline patient needing an unapproved dose frequency, or a herd outbreak requiring therapeutic intervention—the prescribing decision often drifts into casual terminology. Clinical teams frequently speak of off-label prescribing, compounding, and ordering from a pharmacy as if they were interchangeable operational paths. Under federal law, they are not. Every therapeutic administration occupies exactly one distinct regulatory identity.

To answer the central clinical question directly: for any single intended use in a patient, the treatment option must be classified into one of four mutually exclusive legal lanes before anyone crushes a tablet, flavors a solution, or sends a bulk prescription to an outside pharmacy:

1. Lane 1: Labeled use of an approved, conditionally approved, or indexed animal drug. An FDA-approved NADA or ANADA product, a conditionally approved animal drug, or an indexed animal drug, each used exactly as that package is labeled for species, indication, dose, route, frequency, and any withdrawal. Conditionally approved and indexed packages remain labeled use when the intended use matches the label; they are not extra-label-eligible.

2. Lane 2: Finished-Drug Extra-Label Use under AMDUCA (21 CFR Part 530). Actual or intended use of a fully approved finished animal or human drug in a manner not in accordance with approved labeling, validly ordered by a licensed veterinarian within a genuine Veterinarian-Client-Patient Relationship (VCPR).

3. Lane 3: Finished-Product Compounding under 21 CFR 530.13. Preparing a customized medication starting exclusively from an FDA-approved finished animal or human drug product (such as crushing approved tablets into an oral suspension or combining approved injectables), permitted only when no labeled or extra-label finished drug in available dosage forms can appropriately treat the diagnosed condition.

4. Lane 4: Bulk Drug Substance Compounding under FDA CVM GFI #256. Compounding an animal drug directly from pure active pharmaceutical ingredients (bulk chemical substances). This pathway produces an unapproved new animal drug and exists strictly under FDA regulatory enforcement discretion when no FDA-approved, conditionally approved, or indexed drug can be used labeled or extra-label, and an approved finished drug cannot serve as the active ingredient source.

A foundational tenet of federal drug law is that legal identity attaches to the finished commercial package and specific clinical use, not merely to the chemical molecule. A bottle of commercial oral tablets and a jar of pure chemical powder carrying the identical chemical name possess entirely different statutory protections, manufacturing standards, and clinical liabilities. Collapsing these categories can put a use outside 21 CFR 530, produce an unapproved new animal drug, and leave 530.5 records or 530.12 labeling incomplete. Coverage for extra-label or compounded drugs is a separate insurance question.

This guide functions as a rigorous, single-use identity worksheet for practitioners and practice managers. It does not replace the comprehensive criteria for evaluating third-party pharmacies found in our guide on veterinary compounding pharmacy selection, does not replace clinical protocols for backorders detailed in our veterinary drug shortage substitution playbook, does not provide drug monographs for specific agents like doxycycline or cephalexin, and does not replicate the broader regulatory frameworks detailed in our overview of generic veterinary drugs (ANADAs) or the FDA veterinary drug approval process. Furthermore, this guide does not compute patient-specific drug doses or withdrawal intervals.

Read the package: approved, conditionally approved, or indexed

The first physical step in classifying any intended drug use is inspecting the container labeling. Commercial animal pharmaceuticals bear distinct federal regulatory markers that govern their baseline legal status. Practitioners must distinguish among full approval, conditional approval, and index listing before contemplating extra-label use or compounding.

Fully Approved Animal Drugs (NADA and ANADA)

A fully approved animal drug has undergone comprehensive FDA Center for Veterinary Medicine (CVM) review under Section 512 of the Federal Food, Drug, and Cosmetic Act. Pioneer drugs receive a New Animal Drug Application (NADA) approval, while generic equivalents receive an Abbreviated New Animal Drug Application (ANADA) approval based on proven bioequivalence. The container bears a six-digit NADA or ANADA approval number. These products demonstrate substantial evidence of safety and clinical effectiveness for their labeled indications, species, and regimens. Fully approved drugs serve as the primary commercial foundation for veterinary pharmacotherapy and represent the only animal drugs inherently eligible for extra-label use under AMDUCA.

Conditionally Approved Animal Drugs (FD&C Act § 571)

Conditional approval represents a specialized pathway created under Section 571 of the FD&C Act, including the later expansion beyond the original Minor Use and Minor Species pathway, for certain uncommon, serious, or otherwise unmet labeled uses. A conditionally approved drug has demonstrated target-animal safety, but effectiveness is supported by a reasonable expectation of effectiveness rather than the substantial-evidence standard required for full approval. FDA requires labeling that the product is "Conditionally approved by FDA pending a full demonstration of effectiveness under application number XXX-XXX." The same labeling also states that it is a violation of Federal Law to use the product other than as directed in the labeling.

Indexed Animal Drugs (21 CFR 516.155 and 21 U.S.C. § 360ccc-1)

Under Section 572 of the FD&C Act and 21 CFR Part 516, FDA maintains the Index of Legally Marketed Unapproved New Animal Drugs for Minor Species. Indexing is reserved exclusively for non-food-producing minor species (such as ornamental fish, pet birds, or exotic companion mammals) or early, non-food life stages of food-producing minor species. Indexed drugs have been reviewed for safety and manufacturing consistency by an independent expert panel, but they do not hold a full NADA or ANADA approval.

Every indexed drug bears a prominent Minor Species Index File (MIF) number on its label. Under 21 CFR 516.155 and 21 U.S.C. § 360ccc-1(h), the package label must state prominently and conspicuously: "Extra-label use is prohibited." Furthermore, products not intended for food-producing life stages must state: "Not to be used in animals intended for use as food for humans or food-producing animals." Like conditionally approved drugs, indexed drugs cannot be used off-label for any reason.

The Dual-Approval Exception (The New World Screwworm Example)

Clinical confusion occasionally arises when a single commercial pharmaceutical product holds multiple regulatory determinations. FDA CVM practitioner guidance addressing emergency parasite threats, such as New World Screwworm (NWS), identifies a rare but vital legal exception: a small number of animal pharmaceutical products possess a full Section 512 approval (NADA) for primary indications while simultaneously holding a conditional approval or Emergency Use Authorization (EUA) for a secondary indication.

In those narrow cases, extra-label use of that finished product can be 21 CFR 530-eligible solely because the product also holds a full FDA approval, not because a conditional approval or EUA permits extra-label use. Mark whether this SKU is CA-only, indexed-only, or also fully approved. A CA-only or indexed-only package remains extra-label-ineligible.

FDA's GFI #256 Q&A states that compounding animal drugs from FDA-approved, conditionally approved, or indexed drugs as the starting point is generally permissible under certain conditions, and that the resulting compounded drug is not FDA-approved. That Q&A is not 21 CFR 530 extra-label permission to use a conditionally approved or indexed product off its own label. If the intended use is not on the CA or indexed label, extra-label use of that SKU remains prohibited. A different fully approved finished animal or human drug may still be 530-eligible.

Extra-label is a finished-drug lane, and 530.20(a)(1) still applies to dogs and cats

When a clinician determines that an approved animal drug cannot be used according to its labeled instructions, the decision moves into Lane 2: extra-label drug use under the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA), codified at 21 CFR Part 530. Understanding the precise legal boundaries of AMDUCA is critical to maintaining regulatory compliance.

Under 21 CFR 530.3(a), extralabel use means actual use or intended use of a drug in an animal in a manner that is not in accordance with the approved labeling. That includes species, indication, dosage level, frequency, route, or withdrawal time not on the label. Extra-label use under part 530 applies to approved finished animal or human drugs. It does not authorize compounding from bulk drug substances.

Under 21 CFR 530.10, an approved new animal drug or human drug intended for extra-label use is not unsafe under section 512 and is exempt from the labeling requirements of section 502(f) if the use is by or on the lawful written or oral order of a licensed veterinarian within a valid VCPR and in compliance with part 530. Extra-label container labeling under 530.12 still applies. FDA's AMDUCA page restates that extra-label use is limited to circumstances when the health of an animal is threatened, or suffering or death may result from failure to treat, so extra-label use to enhance production is not permitted.

The Companion-Animal Same-Ingredient Gate: 21 CFR 530.30(a)

A widespread myth in small animal veterinary medicine suggests that companion animal veterinarians have unfettered discretion to choose human generic medications over approved veterinary pharmaceuticals simply because human generics may be cheaper or more convenient to stock. Federal regulations explicitly reject this practice.

While 21 CFR 530.30 governs extra-label use in non-food-producing animals (dogs, cats, and horses), paragraph (a) explicitly dictates that the provisions of 21 CFR 530.20(a)(1) apply directly to the use of approved animal drugs in nonfood-producing animals. Under 21 CFR 530.20(a)(1), extra-label use requires that:

This same-ingredient requirement establishes an unmistakable statutory hierarchy: labeled veterinary approved drugs must be considered and exhausted or clinically ruled out before a clinician can lawfully move down the regulatory hierarchy to extra-label finished drugs, finished-drug compounding, or bulk substance compounding.

Food-animal gates and the 530.41 / 530.11 stop list

While companion animal medicine focuses heavily on individual patient safety and clinical efficacy, food-producing animal medicine introduces strict public health mandates designed to prevent toxic or antimicrobial residues from contaminating meat, milk, and eggs entering the human food chain. When managing food-producing animals, 21 CFR Part 530 erects rigorous clinical gates and an absolute statutory stop list.

Mandatory Gates Under 21 CFR 530.20 for Food Animals

Before a licensed veterinarian may prescribe an approved animal or human drug for extra-label use in food-producing species, 21 CFR 530.20 mandates four non-negotiable operational requirements:

• Careful Medical Diagnosis: The prescribing veterinarian must make a thorough clinical diagnosis within the scope of a valid VCPR before instituting extra-label therapy.

• Scientifically supported extended withdrawal: before extra-label use in food animals, the veterinarian must establish a substantially extended withdrawal period supported by appropriate scientific information. FDA's extra-label resource names FARAD as one such source; it is not the only lawful source, and this page does not calculate an interval.

• Positive Animal Identification: The veterinarian and livestock producer must institute robust, verifiable procedures to maintain the individual or group identity of all treated animals throughout the treatment and withdrawal periods.

• Residue Avoidance Assurance: The veterinarian must take active measures to verify that assigned withdrawal periods are observed and that no illegal drug residues enter the food supply.

Furthermore, 21 CFR 530.20(b) establishes that if an approved human drug or an animal drug approved only for nonfood animals is used in a food-producing animal, the veterinarian must have a documented medical rationale. If human food safety data is completely unavailable, the veterinarian and owner must ensure that the treated animal and all its food products permanently remain outside the human food supply. Under 21 CFR 530.20(c), extra-label use of an approved human drug is expressly prohibited if an approved animal drug labeled for food animals can be used in an extra-label manner to treat the diagnosed condition.

Statutory Prohibitions Under 21 CFR 530.11 and 530.41

Federal regulations establish absolute limitations where extra-label use is categorically deemed unsafe, invalidating any claim of veterinary discretion:

• Lay Person Administration (21 CFR 530.11(a)): Extra-label use by any lay individual is illegal, except when performed under the direct written or oral supervision of a licensed veterinarian within a valid VCPR.

• In-Feed Extra-Label Prohibition (21 CFR 530.11(b)): Extra-label use of any approved new animal drug or human drug in or on animal feed is strictly prohibited by federal statute. Medicated feed must be fed exactly as labeled. While FDA Compliance Policy Guide (CPG) 615.115 articulates limited regulatory enforcement discretion for certain minor species feeds, it does not legalize feed extra-label use under AMDUCA.

• Public Health Residue Risk (21 CFR 530.11(c)-(d)): Any extra-label use that results in a drug residue presenting a risk to public health, or that exceeds safe concentrations or established tolerances, is deemed unsafe under Section 512.

• Prohibited Drug Classes in Food Animals (21 CFR 530.41(a)): FDA maintains an absolute statutory ban on the extra-label use of specific drugs and drug classes in food-producing animals under any circumstances, regardless of veterinary oversight or extended withdrawal.

Importantly, 21 CFR 530.41(b) currently reserves the section for drugs prohibited from extra-label use in nonfood-producing animals. As FDA's educational resource The Ins and Outs of Extra-Label Drug Use in Animals confirms, there are currently no approved drugs prohibited from extra-label use in companion animals (dogs, cats, and horses). However, this reservation must not be confused with blanket authorization: it does not permit extra-label use of conditionally approved or indexed drugs, and it does not waive the same-ingredient gate established by 21 CFR 530.20(a)(1).

530.13 finished-product compounding is still extra-label, not GFI #256

When a patient requires a formulation, strength, or route that is not commercially manufactured, the question of pharmaceutical compounding arises. Here lies one of the most critical legal dividing lines in veterinary practice: compounding from an FDA-approved finished drug under AMDUCA (Lane 3) versus compounding from a bulk chemical substance under FDA guidance (Lane 4).

Under 21 CFR 530.13(a), the regulation states:

AMDUCA does not authorize, protect, or regulate compounding from bulk chemical powders. 21 CFR 530.13 applies part 530 to compounding from approved animal or human drugs and states that nothing in the part shall be construed as permitting compounding from bulk drugs. Under 21 CFR 530.13(b), that finished-product extra-label compounding is permitted only when all of the following conditions are met:

1. Full Part 530 Compliance: All general provisions of 21 CFR Part 530 (including a valid VCPR, therapeutic rationale, medical recordkeeping, and compliant container labeling) must be satisfied.

2. No Suitable Approved Product: There must be no commercial approved new animal drug or approved human drug that, when used as labeled or in conformity with Part 530, will in the available dosage form and concentration appropriately treat the diagnosed condition.

3. Licensed Professional Execution: The compounding must be performed by a licensed pharmacist or a licensed veterinarian within the legitimate scope of professional veterinary practice.

4. Safety and Efficacy Assurance: Adequate clinical procedures and pharmaceutical controls must be maintained to ensure the safety, stability, and therapeutic efficacy of the finished compound.

5. Commensurate scale: the scale of the compounding operation must be commensurate with the established need for compounded products (for example, similar to that of comparable practices).

6. State Law Adherence: The preparation must comply with all applicable state pharmacy acts and veterinary medical board regulations.

In food-producing animals, 21 CFR 530.13(b)(2) imposes an additional statutory restriction: compounding from an approved human drug is prohibited if an approved animal drug can be used as the starting material for the compounded formulation.

Crushing, Flavoring, and Mixing: AMDUCA vs GFI #256

In routine clinical practice, technicians and veterinarians frequently perform minor medication modifications: crushing commercial tablets into an applesauce paste for a dysphagic dog, adding commercial flavoring syrup to an unpalatable oral liquid for a cat, or drawing up two compatible injectable medications into a single syringe for premedication. Practice teams often wonder whether these actions trigger federal scrutiny under FDA's bulk compounding policies.

FDA's GFI #256 Q&A Question 8 states that GFI #256 does not address compounding using FDA-approved drugs, because that is already extra-label use under AMDUCA and 21 CFR 530. Common practices such as crushing tablets of an FDA-approved medication into a paste or liquid, adding flavor, or combining two injectable medications in a syringe are generally acceptable under certain conditions described in AMDUCA. Those acts are not GFI #256 bulk compounding. They are 530.13 questions only when the 530.13(b) conditions are actually met, including that no approved animal or human drug, used as labeled or in conformity with part 530, will in the available dosage form and concentration appropriately treat the diagnosed condition. A flavor request is not automatically 530-compliant.

However, veterinarians must recognize that a compounded preparation created from an approved drug is not an FDA-approved drug. Compounding alters the physical matrix, dissolution profile, and stability of the original commercial product. The resulting preparation does not carry FDA approval, has not undergone pharmacokinetic bioequivalence testing, and cannot claim manufacturer stability beyond scientifically validated beyond-use dates (BUDs).

GFI #256 bulk: copies, office stock, and what the guidance is not

When neither labeled use (Lane 1), extra-label finished-drug use (Lane 2), nor finished-product compounding (Lane 3) can provide a medically viable therapy, clinical teams turn to Lane 4: compounding from bulk drug substances. Understanding the non-statutory nature of this lane is essential for legal risk management.

The Legal Architecture of FDA CVM GFI #256

On April 14, 2022, the FDA announced the availability of final Guidance for Industry (GFI) #256, titled Compounding Animal Drugs from Bulk Drug Substances (87 FR 22212). Despite outdated secondary literature that still refers to GFI #256 as a draft document, it has been an active, finalized federal policy since 2022.

Crucially, GFI #256 does not authorize or legalize bulk compounding. Under the Federal Food, Drug, and Cosmetic Act, compounding an animal drug from a bulk chemical substance (raw active pharmaceutical ingredient powder) results in a new animal drug that violates Section 512 (lack of pre-market approval), Section 501(a)(2)(B) (failure to comply with Current Good Manufacturing Practice, CGMP), and Section 502(f)(1) (failure to bear adequate directions for use). Instead, GFI #256 articulates FDA's regulatory enforcement discretion policy—specifying the narrow circumstances under which the agency generally does not intend to initiate enforcement action against state-licensed pharmacies, federal facilities, or veterinarians.

Under GFI #256, bulk compounding is considered medically necessary only when a strict two-part prerequisite is satisfied:

1. There is no medically appropriate FDA-approved, conditionally approved, or indexed drug to treat the patient (either used as labeled or in an extra-label manner); AND

2. An FDA-approved finished drug cannot be used as the starting source of the active ingredient.

If an approved finished tablet or capsule exists and can be crushed or reconstituted to form the needed formulation, compounding that preparation from raw bulk chemical powder violates the fundamental terms of GFI #256.

The Four Narrow Scopes of GFI #256

GFI #256 limits its enforcement discretion to four strictly defined operational categories:

• Patient-Specific Prescriptions for Nonfood-Producing Animals: Compounding from bulk to fill an individualized prescription for an identified companion animal (dog, cat, horse) under a valid VCPR.

• Office Stock for Nonfood-Producing Animals: Compounding unassigned inventory for clinic use without a patient-specific prescription. Office stock from bulk is strictly restricted to active substances listed on FDA's dynamic List of Bulk Drug Substances for Compounding Office Stock Drugs for Use in Nonfood-Producing Animals (or substances actively nominated and under review), and is permitted only when an urgently needed compound must be administered immediately to avoid animal suffering or death, such that waiting for a patient-specific compound is clinically unfeasible.

• Antidotes for Food-Producing Animals: Compounding specific emergency antidotes for livestock from bulk substances specifically identified on FDA's food-animal antidote list, accompanied by scientifically established withdrawal intervals.

• Sedatives and Anesthetics for Free-Ranging Wildlife: Compounding immobilization agents from bulk substances for wildlife management under qualified veterinary supervision.

The Compounded 'Copy' Rules and Medical Rationales

FDA views compounded animal drugs that replicate commercial approved drugs as a direct threat to the animal drug approval system. Under GFI #256, a compounded preparation is classified as a copy if it contains the same active moiety, uses the same route of administration, and has the same, similar, or easily substitutable dosage strength as an FDA-approved animal or human drug.

Compounding a copy from a bulk drug substance is an active enforcement priority for FDA unless the prescribing veterinarian documents a specific patient-specific medical rationale explaining why the commercial product cannot be used. FDA's guidance is uncompromising on what does not qualify:

Drug Shortages Are Not Blanket Copy Permissions

A frequent point of friction occurs during commercial backorders. Clinical teams often assume that when an approved drug is listed on FDA's animal drug shortage database, pharmacies may automatically mass-compound copies from bulk powder. FDA's GFI #256 Q&A (Questions 24, 25, and 51) clarifies that a commercial shortage is not a blanket exemption. While the complete commercial unavailability of an approved finished drug may provide the clinical justification for why the approved finished drug cannot serve as the source material for compounding, the order must still be patient-specific and comply with all remaining GFI #256 criteria. For comprehensive backorder management, clinics should follow our established veterinary drug shortage substitution playbook.

The Boundary of Draft GFI #256B (August 2026)

In August 2026, FDA CVM released draft Guidance for Industry #256B, titled Compounding Animal Drugs from Bulk Drug Substances: Compounding under CGMP in Federally-Registered Facilities (Docket No. FDA-2018-D-4533). Draft GFI #256B addresses animal drug compounding under Current Good Manufacturing Practice regulations in facilities registered under Section 503B(b) (human outsourcing facilities) or Section 510(b) of the FD&C Act.

Veterinarians and practice leaders must understand two critical legal boundaries regarding Draft GFI #256B:

1. It is a draft guidance document labeled NOT FOR IMPLEMENTATION. Public comments remain open through November 27, 2026. It does not represent active, enforceable policy and cannot be cited to justify clinical practices today.

2. It is a facility-scope addendum, NOT a fifth legal lane. Draft GFI #256B applies exclusively to bulk drug substance compounding in registered 503B and 510 facilities. It does not apply to compounding from approved finished animal or human drugs, does not legalize bulk compounding, and does not authorize 503B outsourcing facilities to distribute compounded animal copies outside the strict medical necessity boundaries established in GFI #256.

graph TD
  A["One intended use"] --> B{"Is a fully approved, CA, or indexed package labeled for this species, indication, form, and regimen?"}
  B -- "Yes: use that package as labeled" --> C["LANE 1: Labeled use of that package"]
  B -- "No: intended use is not on that label" --> D{"Is the candidate SKU CA-only or indexed-only?"}
  D -- "Yes: extra-label of this SKU is prohibited" --> E["STOP extra-label of this SKU; a different fully approved finished drug may still be 530-eligible"]
  D -- "No: fully approved finished animal or human drug" --> F{"Can that finished drug be used extra-label under 21 CFR 530, including 530.20(a)(1)?"}
  F -- "Yes: valid VCPR and therapeutic need" --> H["LANE 2: Extra-label finished-drug use"]
  F -- "No: form or concentration unsuitable" --> I{"Can an approved finished drug be the 530.13 starting material?"}
  I -- "Yes: crush, flavor, or combine only if 530.13(b) holds" --> J["LANE 3: 530.13 finished-product compounding"]
  I -- "No: approved finished drug cannot be the source" --> K{"Does GFI #256 bulk enforcement discretion even apply?"}
  K -- "Yes: patient-specific nonfood or listed office stock / named scopes" --> L["LANE 4: Bulk compounding; still an unapproved new animal drug"]
  K -- "No: convenience or price copy, or other mismatch" --> M["Unapproved new animal drug; 530 does not authorize bulk"]

VCPR, 530.5 records, and 530.12 labeling still have to be present

Whenever a clinician departs from labeled use (Lane 1) and enters extra-label finished-drug prescribing (Lane 2) or finished-product compounding (Lane 3), federal law imposes rigorous administrative and labeling duties. These requirements are statutory conditions of legality: failure to maintain mandatory records or container labeling deems the drug unsafe and adulterated under Section 512.

The Federal VCPR Mandate (21 CFR 530.3(i))

Under 21 CFR 530.3(i), a valid Veterinarian-Client-Patient Relationship exists only when all three federal elements are satisfied:

1. Assumption of medical responsibility: the licensed veterinarian has assumed responsibility for making medical judgments regarding the health of the animal(s) and the need for medical treatment, and the client has agreed to follow the veterinarian's instructions.

2. Sufficient Personal Knowledge: The veterinarian possesses sufficient personal knowledge of the animal(s) to initiate at least a general or preliminary medical diagnosis. Federal law explicitly dictates that such knowledge exists only when the veterinarian has recently seen and is personally acquainted with the keeping and care of the animal(s) by virtue of a physical examination and/or medically appropriate and timely visits to the premises where the animals are kept.

3. Ready availability for follow-up: the practicing veterinarian is readily available for follow-up in case of adverse reactions or failure of the regimen of therapy.

Practitioners must note that while 21 CFR 530.3(i) establishes the federal regulatory floor for extra-label drug use, state veterinary medical boards may establish stricter physical examination frequency requirements or telemedicine limitations. Clinicians must always adhere to the more stringent applicable standard.

Mandatory Veterinary Medical Records (21 CFR 530.5)

Under 21 CFR 530.5, as a condition of extra-label use, veterinarians shall maintain records of extra-label uses. Those records shall be adequate to substantiate the identification of the animals and shall provide the following information:

• Animal identification. The chapeau of 21 CFR 530.5(a) requires records adequate to substantiate identification of the animals, kept as individual records or, in food-animal practice, on a group, herd, flock, or per-client basis.

• 21 CFR 530.5(a)(1). The established name of the drug and its active ingredient, or if formulated from more than one ingredient, the established name of each ingredient.

• 21 CFR 530.5(a)(2). The condition treated.

• 21 CFR 530.5(a)(3). The species of the treated animal(s).

• 21 CFR 530.5(a)(4). The dosage administered.

• 21 CFR 530.5(a)(5). The duration of treatment.

• 21 CFR 530.5(a)(6). The numbers of animals treated.

• 21 CFR 530.5(a)(7). The specified withdrawal, withholding, or discard time(s), if applicable, for meat, milk, eggs, or any food which might be derived from any food animals treated.

Under 21 CFR 530.5(b), a veterinarian shall keep all required records for 2 years or as otherwise required by Federal or State law, whichever is greater. 21 CFR 530.5(c) requires that any person in charge, control, or custody of such records permit a person designated by FDA, at all reasonable times, to have access to, copy, and verify those records.

Mandatory Container Labeling (21 CFR 530.12)

Any drug dispensed for extra-label use or compounded under 530.13 must bear an attached, durable container label at the time of dispensing. Under 21 CFR 530.12, the label must include:

• Veterinarian / Pharmacy Contact: The name and address of the prescribing veterinarian. If the medication is dispensed by an outside retail or compounding pharmacy, the label must state the prescribing veterinarian's name plus the dispensing pharmacy's name and address.

• Active Ingredients: The established name of each active ingredient.

• Directions for Use: Complete clinical directions, including the class, species, or specific identification of the animal(s); the exact dosage; dosing frequency; route of administration; and duration of therapy.

• Cautionary Statements: Any required cautionary warnings, storage requirements, or adverse reaction warnings.

• Assigned Withdrawal Times: For food-producing animals, the specific withdrawal, withholding, or discard time established by the veterinarian for meat, milk, eggs, or animal byproducts.

One labeled fictional worksheet, and what this page does not decide

To integrate these principles into a practical clinic workflow, examine the following simulated case evaluation. This packet is an educational identity classification exercise: it is stamped fictional and must not be mistaken for an actual veterinary prescription, dispensing order, or clinical dosing guide.

What This Guide Does Not Decide

To maintain clinical and legal integrity, practitioners must recognize the strict operational boundaries of this worksheet:

• No Dosing Calculations or Therapeutic Advice: This worksheet establishes legal identity; it does not provide clinical drug dosages, dosing intervals, or medical treatment plans. Prescribing decisions remain the sole professional responsibility of the attending licensed veterinarian.

• No food-animal withdrawal arithmetic: withdrawal intervals for extra-label food-animal therapies must be supported by appropriate scientific information under 21 CFR 530.20. FDA's extra-label resource names FARAD as one such source. This worksheet does not calculate an interval.

• No Pharmacy Credentialing or Facility Audit: Selecting an outside compounding pharmacy requires verifying 503A state licensure, sterile testing protocols, and GFI #256 compliance red flags, as detailed in our guide on veterinary compounding pharmacy selection.

• No Commercial Shortage Substitution Protocol: When managing commercial manufacturer backorders, clinics must follow structured tier substitution protocols outlined in our veterinary drug shortage substitution playbook.

• No Insurance Reimbursement Determination: Coverage for extra-label prescribing and compounded medications varies significantly across pet health insurance underwriters. For policy exclusions and claims analysis, consult our guide on pet insurance prescription coverage.

• No Replacement for State Law: This guide addresses U.S. federal regulatory identity under the FD&C Act, 21 CFR, and FDA CVM guidance. Individual state veterinary medical practice acts and state boards of pharmacy enforce independent requirements that may be more restrictive than federal law.

Sources

This reference worksheet is grounded exclusively in primary federal statutory provisions, formal regulations codified in the Code of Federal Regulations, and official guidance documents published by the U.S. Food and Drug Administration Center for Veterinary Medicine:

• U.S. National Archives / FDA. 21 CFR 530.3 — Definitions (Extralabel Drug Use in Animals). Defines extra-label drug use, valid veterinarian-client-patient relationship (VCPR), and nonfood-producing animals.

• U.S. National Archives / FDA. 21 CFR 530.5 — Veterinary Records. Mandates two-year retention of patient identification, active ingredients, dosage, duration, and FDA inspection access.

• U.S. National Archives / FDA. 21 CFR 530.10 — Provision Permitting Extralabel Use of Animal Drugs. States that extra-label use of an approved new animal or human drug is not unsafe under section 512, and is exempt from section 502(f) labeling, if it is by or on a lawful veterinarian order within a VCPR and in compliance with part 530.

• U.S. National Archives / FDA. 21 CFR 530.11 — Limitations on Extralabel Use. Prohibits lay-person administration, extra-label use in or on animal feed, and uses resulting in public health residue risks.

• U.S. National Archives / FDA. 21 CFR 530.12 — Labeling Requirements. Details mandatory container labeling including prescribing veterinarian, active ingredients, directions, and withdrawal times.

• U.S. National Archives / FDA. 21 CFR 530.13 — Extralabel Use from Compounding of Approved New Animal and Approved Human Drugs. Applies part 530 to compounding from approved finished animal or human drugs and states that nothing in the part shall be construed as permitting compounding from bulk drugs.

• U.S. National Archives / FDA. 21 CFR 530.20 — Conditions for Permitted Extralabel Animal and Human Drug Use in Food-Producing Animals. Establishes the 530.20(a)(1) same-ingredient gate, scientific withdrawal requirements, and human-drug sequencing.

• U.S. National Archives / FDA. 21 CFR 530.30 — Extralabel Drug Use in Nonfood Animals. Extends extra-label finished-drug provisions to companion animals and explicitly incorporates 530.20(a)(1).

• U.S. National Archives / FDA. 21 CFR 530.41 — Drugs Prohibited for Extralabel Use in Animals. Enumerates statutory prohibited drug classes in food-producing animals and reserves companion-animal list.

• U.S. Food and Drug Administration. Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA). Regulatory overview of veterinary extra-label authority, therapeutic limits, and finished-drug boundaries.

• U.S. Food and Drug Administration. The Ins and Outs of Extra-Label Drug Use in Animals: A Resource for Veterinarians. CVM practitioner guidance detailing VCPR, records, labeling, food-animal gates, and companion-animal provisions.

• U.S. Food and Drug Administration. Conditional Approval Explained: A Resource for Veterinarians. Details Section 571 statutory requirements and confirms that extra-label use of conditionally approved animal drugs is illegal.

• U.S. National Archives / FDA. 21 CFR 516.155 — Labeling of Indexed Drugs. Mandates MIF numbering and the prominent required container statement: 'Extra-label use is prohibited.'

• U.S. Congress / Legal Information Institute. 21 U.S.C. § 360ccc-1 — Index of Legally Marketed Unapproved New Animal Drugs for Minor Species. Statutory authority establishing indexing and statutory extra-label prohibition for indexed products.

• U.S. Food and Drug Administration. New World Screwworm: Information for Veterinarians. Explains that extra-label eligibility is limited to full FDA approvals and articulates the dual-approval NADA exception.

• U.S. Food and Drug Administration. Aquaculture and Aquaculture Drugs Basics. Outlines packaging status, six-digit MIF labeling mandates, and strict on-label compliance requirements.

• U.S. Food and Drug Administration. CVM GFI #256 — Compounding Animal Drugs from Bulk Drug Substances. Final guidance describing FDA enforcement discretion priorities for compounding animal drugs from raw chemical APIs.

• Federal Register. Compounding Animal Drugs From Bulk Drug Substances; Final Guidance Availability (87 FR 22212). April 14, 2022 notice formalizing final issuance of CVM GFI #256.

• U.S. Food and Drug Administration. Q&A: GFI #256 — Compounding Animal Drugs from Bulk Drug Substances. Comprehensive guidance Q&A confirming that crushing/flavoring approved finished drugs is AMDUCA, defining copies, and establishing medical rationales.

• U.S. Food and Drug Administration. Animal Drug Compounding Regulatory Hub. Core agency reference establishing the prerequisite hierarchy: bulk compounding is considered only when approved drugs cannot serve as source material.

• U.S. Food and Drug Administration. List of Bulk Drug Substances for Compounding Office Stock Drugs for Use in Nonfood-Producing Animals. Dynamic FDA list of bulk drug substances for compounding office-stock drugs for nonfood-producing animals under GFI #256 enforcement discretion; listing is not a 530 extra-label authorization.

• U.S. Food and Drug Administration. Draft CVM GFI #256B — Compounding Animal Drugs from Bulk Drug Substances Under CGMP in Federally-Registered Facilities. August 2026 draft guidance outlining proposed enforcement discretion for 503B and 510 registered establishments.